|
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News Archive - July 2022
REALIZE At #AIDS2022
July 31, 2022 - Long-term advocate Colleen Price explains the issue of chronic pain in HIV-positive people as an episodic disability at the Disability Networking Zone.
Global Fund Reports Significant Progress in Breaking Down Human Rights-Related Barriers to HIV and TB Services
MONTREAL - July 31, 2022 - A new report released by the Global Fund today at the 24th International AIDS Conference unveils key findings of the activities supported by the Global Fund’s Breaking Down Barriers initiative, a groundbreaking program launched in 2017 to provide intensive financial and technical support to 20 countries* to address stigma and discrimination, criminalization and other human rights-related obstacles that continue to threaten progress against HIV, tuberculosis (TB), and malaria.
Smart new single-cell assay shines a light on the HIV reservoir
31 July 2022 - Gus Cairns - New ‘FIND-Seq’ assay hailed as game-changing tool in HIV cure researchThe 24th International AIDS Conference (AIDS 2022) in Montreal heard on Friday that for the first time scientists have developed a sensitive gene assay that can specifically find the tiny subset of ‘reservoir’ cells that harbour silent HIV infection by using nanotechnology to detect their distinct genetic signature.
Read more...
Global AIDS leaders raise alarm on the danger of millions of preventable deaths stating that only bold action to tackle inequalities can end the AIDS pandemic
MONTREAL/GENEVA, 30 July 2022 - Global AIDS leaders have joined forces in issuing a strong warning that derailing of progress to end AIDS is putting millions of people in danger. They came together to launch UNAIDS Global AIDS Update 2022, ahead of the opening of the 24th International AIDS Conference currently taking place in Montreal, 29 July to 2 August.
“The data we are sharing brings painful but vital news,” said Winnie Byanyima, Executive Director of UNAIDS. “The latest findings reveal that the response to the AIDS pandemic has been derailed by global crises, from the colliding pandemics of HIV and COVID, to the war in Ukraine and the resulting global economic crisis. Progress has been stalled, inequalities have widened, resources have shrunk, and millions of lives are now at risk.”
AIDSVu Releases New Data Showing Significant Inequities in PrEP Use Among Black and Hispanic Americans
ATLANTA – July 29, 2022 - Black people represented 14% of PrEP users in 2021, but 42% of new HIV diagnoses in 2020, while Hispanic/Latinx people represented 17% of PrEP users in 2021 and 27% of new HIV diagnoses in 2020.
Today, AIDSVu released the first-ever publicly available state-level PrEP use data and maps by race/ethnicity from 2012 to 2021, showing that while PrEP use has increased on average 56% each year since its approval in 2012, there are significant inequities in PrEP use among Black and Hispanic people and in the Southern region of the country. In 2021, there were only 3 Black and 6 Hispanic/Latinx PrEP users for each new HIV diagnosis within those racial/ethnic groups, compared to 26 white PrEP users for each new HIV diagnosis among white people. In the South, there were 7 PrEP users for each new HIV diagnosis in the region, compared to 15 PrEP users for each new HIV diagnosis in the Northeast.
Demanding more funding for HIV/AIDS at AIDS Conference in Montreal
Jul 29, 2022 - CityNews - "We need to get back on track," says Maurine Murenga an advocate for HIV/AIDS research, at the International AIDS conference in Montreal. Without the Government of Canada's pledge of $1.2 billion, she says it could be deadly. Felisha Adam reports.
Canada has fallen behind on diagnosing and treating people with HIV
July 29, 2022 - SEAN ROURKE, TREVOR STRATTON, NOTISHA MASSAQUOI AND BILL FLANAGAN
CONTRIBUTED TO THE GLOBE AND MAIL
The number of new HIV cases in Canada has been on the rise over the past five years, and in 2020 (our most recent national estimates of HIV surveillance), four people were infected with HIV every day. However, this is likely an underestimate – we expect to see a higher rate of new HIV infections in 2021 and 2022 because COVID-19 significantly restricted access to HIV testing and treatment.
Read more...
WHO @ AIDS 2022
29 July – 2 August 2022 Montreal, Canada, and virtually
WHO will participate in AIDS 2022, the 24th International AIDS Conference which will take place both in Montreal, Canada and virtually. WHO Department of Global HIV, hepatitis and sexually transmitted infections Programmes (HHS) will hold a number of key plenary and satellite sessions to present new guidelines, introduce the new Global Health Sector Strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030, launch a new joint UNICEF-UNAIDS-WHO initiative on to end AIDS in children, and to share its latest scientific and normative work.
Read more...
Mistakes in handling HIV/AIDS pandemic could hinder monkeypox response, advocates say
Jul 29, 2022 - Nick Logan - UN officials fear monkeypox, COVID-19 and other threats are slowing progress in battle against HIV/AIDS
Top health officials say they are trying to limit the spread of the monkeypox virus while also preventing stigma against those most affected — particularly gay, bisexual and other men who have sex with men — but their messaging may be a part of the problem, according to some advocates.
More than 21,000 people, in over 70 countries, have contracted the virus, which causes painful sores and blisters among other symptoms.
Read more...
Visa denials denounced at Montreal AIDS conference, federal minister cancels speech
July 29, 2022 - The president of the International AIDS Society says her organization will re-evaluate how it organizes international conferences as a result of visa denials by the Canadian government.
Adeeba Kamarulzaman told attendees at the opening ceremony of the AIDS 2022 conference Friday morning in Montreal that "many" delegates, including staff members and leadership of her organization, were unable to get visas to attend.
Read more...
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced
London, 29 July 2022 - Week 240 data from the BRIGHTE-study of first-in-class fostemsavir continue to show improvement in immunologic response and favourable virologic outcomes
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced week 240 results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns.
 
Journal of the International AIDS Society publishes special issue on HIV and stigma
29 July 2022 (Montreal, Canada) - The Journal of the International AIDS Society (JIAS) has launched a special issue, titled “Getting to the heart of stigma across the HIV continuum of care”, at AIDS 2022, the 24th International AIDS Conference.
The content of the special issue was guided by Guest Editors Lucy Stackpool-Moore (International AIDS Society, Switzerland, and Watipa, Australia), Carmen H Logie (University of Toronto, Canada) and Allanise Cloete (Human Sciences Research Council, South Africa).
Leaders At AIDS 2022 Warn That The World Is Losing Ground Against HIV
29 July 2022 (Montreal, Canada) - HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more
More than 9,500 in-person and nearly 2,000 virtual participants are registered to attend the fully hybrid AIDS 2022, the 24th International AIDS Conference. The conference takes place from 29 July to August 2 in Montreal and virtually.
World Hepatitis Day 2022
28 Jul 2022 - World Hepatitis Day is marked on 28 July each year to increase the awareness and understanding of viral hepatitis.
There are an estimated 4.7 million chronic hepatitis B virus (HBV) cases and 3.9 million chronic hepatitis C virus (HCV) cases in the European Union/European Economic Area (EU/EEA). As many people who are infected with hepatitis B or C do not show symptoms, this ‘silent disease’ is often not diagnosed. Left untreated, chronic infection with hepatitis B and C may progress to liver cirrhosis or cancer.
Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced data from two poster presentations at the 24th International AIDS Conference (“AIDS 2022”), being held from July 29 to August 2 in Montreal, Canada and virtually. The new data provide key understandings on the potential of Trogarzo® (ibalizumab) to evolve treatment paradigms for heavily treatment-experienced HIV populations on complex regimens.
Canada Pavilion at AIDS 2022
SAN FRANCISCO - July 28, 2022 - The International AIDS Conference is the world’s premier platform for marking achievements, celebrating success, and setting strategic directions in the global HIV/AIDS response. The 24th International AIDS Conference, AIDS 2022: Montreal, Canada, and virtually will be held from July 29 to August 2, 2022.
The Canadian Association for Global Health (CAGH) is coordinating the Canada Pavilion at AIDS 2022 with the the support of the National Advisory Committee (representatives from over 25 different community organizations and individuals engaged in Canada’s HIV response).
Under the theme of Solidarity. Science. Support., the Canada Pavilion is an an exploration of the strength, innovation and community behind Canada’s HIV/AIDS response.
Visit the different elements of the Canada Pavilion:
San Francisco declares emergency over monkeypox spread
SAN FRANCISCO - July 28, 2022 - The mayor of San Francisco announced a state of emergency Thursday over the growing number of monkeypox cases, allowing officials to cut through red tape and fight a public health crisis reminiscent of the AIDS epidemic that began devastating the city in the 1980s.
Read more...
American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
Beginning the analytic treatment interruption is a pivotal step to potentially demonstrating a gene therapy cure for HIV.
July 28, 2022 - American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure clinical trial: it began withdrawing participants from their antiretroviral drugs earlier this month. This clinical protocol, technically known as analytic treatment interruption (ATI), may ultimately determine if this gene therapy treatment can cure HIV.
“This is the next logical step in the trial’s progression,” explained Dr. Marcus A. Conant, Chief Medical Officer at American Gene Technologies. “By withdrawing these patients’ antiretrovirals we can demonstrate whether our AGT103-T gene therapy will lead to a cure.”
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
July 28, 2022 - FOSTER CITY, Calif.--(BUSINESS WIRE)-- – ALLIANCE Trial Highlights Potential of Biktarvy for Adults with HIV and HBV Coinfection –
– Key Initiatives Highlight Role of Catalytic Collaboration to Help End the Epidemic for Everyone, Everywhere –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a highly efficacious treatment option for a broad range of people with HIV, including individuals with HIV/hepatitis B (HBV) coinfection. Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential suppression of HBV and HIV suppression comparable to an alternative HIV regimen. Additionally, 5-year data from two Phase 3 trials further demonstrated Biktarvy’s sustained efficacy, safety profile and high barrier to resistance in adults with HIV initiating therapy. The data were presented at the 24th International AIDS Conference (AIDS 2022).
HVTN at the 24th International AIDS Conference in Montreal
SEATTLE (Thursday, July 28, 2002) - Despite scientific breakthroughs, millions of lives needlessly lost to HIV
Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2.
HVTN, based at the Fred Hutchinson Cancer Center in Seattle with an international network of AIDS and HIV experts, will be involved in more than a dozen oral, poster and other presentations.
Momentum builds to deliver long-acting PrEP for HIV prevention
28 July 2022 (Montreal, Canada) - New research, WHO guidelines, voluntary licensing agreement and global coalition announced at AIDS 2022
A series of announcements today ahead of AIDS 2022, the 24th International AIDS Conference – including late-breaking study results, new WHO guidelines, a major voluntary licensing agreement and a new global coalition – built momentum for global access to long-acting cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
ViiV HEALTHCARE AND THE MEDICINES PATENT POOL SIGN NEW VOLUNTARY LICENSING AGREEMENT TO EXPAND ACCESS TO INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE
London, July 28, 2022 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool (MPP) today announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries
UNAIDS welcomes ViiV’s agreement to enable generic production of long acting PrEP to 90 countries
MONTREAL/GENEVA, 28 July 2022 - UNAIDS welcomes the agreement between ViiV and the Medicines Patent Pool to enable access to generic formulation of long acting Cabotegravir for PrEP to 90 low- and lower-middle income countries.
ViiV HEALTHCARE ANNOUNCES NEW DATA AT AIDS 2022 FROM UNBLINDED PHASE OF HPTN 084 STUDY IN WOMEN IN SUB SAHARAN AFRICA SHOWING CONTINUED SUPERIOR EFFICACY OF INJECTABLE CABOTEGRAVIR LONG-ACTING FOR PREP OVER DAILY, ORAL TDF/FTC TABLETS
London, July 28, 2022 - No new HIV infections were observed in participants who initiated cabotegravir injections in the year following study unblinding
No birth defects reported among women who became pregnant after exposure to initial injections of cabotegravir for PrEP
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced new efficacy and safety findings from the unblinded period of the HIV Prevention Trials Network (HPTN) 084 trial evaluating cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) in women in sub Saharan Africa.
New insights into HIV latent cells yield potential cure targets
July 27, 2022 - In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
July 27, 2022 - FOSTER CITY, Calif.- Gilead Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) resubmission for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 27, 2022.
Beyond the blood-brain barrier: HIV research at Texas Biomed gets NIH funding boost
SAN ANTONIO (July 27, 2022) - The $3.9 million grant supports research exploring how gene-editing technology may help eradicate HIV in the brain.
Finding a cure for HIV has been extremely difficult, in part because the virus hides from antiretroviral treatments in one of the hardest places to reach: the brain.
People With HIV Now Face Chronic Disease In Living Longer
MONTREAL, July 27 - By Boo Su-Lyn - Dr Adeeba Kamarulzaman notes that diabetes kills more people than HIV in South Africa and that the burden from NCDs, like hypertens ion, cardiovascular disease, and cancer, is increasing globally.
Scientists and health advocates are calling for better integration of non-communicable disease (NCD) care with HIV services for people living with HIV who are now living longer lives.
Pre-conference activities begin as Canada hosts 24th International AIDS Conference in Montreal
MONTREAL, July 27, 2022 /CNW/ - The Government of Canada is pleased to welcome the world to Montreal as Canada hosts AIDS 2022, the 24th International AIDS Conference. The conference brings together scientists, clinicians, community leaders, advocates, people with lived experience of HIV, health providers, decision-makers and others from around the world to advance HIV research, shift evidence into action, and accelerate progress toward the shared goal of ending HIV and AIDS as a public health concern by 2030.
Patient with HIV achieves remission following stem cell transplant at City of Hope
July 27, 2022 - By Letisia Marquez - The individual, who was treated for leukemia, is the fourth in the world and the oldest to go into long-term remission of HIV after receiving stem cells from a donor with a rare genetic mutation
City of Hope announced July 27 that a 66-year-old man who was diagnosed with HIV in 1988 has been in remission from the virus for over 17 months after stopping antiretroviral therapy (ART) for the disease following a stem cell transplant from an unrelated donor for acute leukemia. Jana K. Dickter, M.D., City of Hope associate clinical professor in the Division of Infectious Diseases, presented the data at the AIDS 2022 press conference. The patient received the transplant nearly 3 1/2 years ago at City of Hope.
IAS statement on “In Danger: UNAIDS Global AIDS Update 2022”
27 July 2022 - The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched its annual report on the state of the global HIV response today ahead of AIDS 2022, the 24th International AIDS Conference, in Montreal, Canada, at a live event also livestreamed at www.unaids.org.
“We cannot afford to lose more ground in the global response to HIV. Seventy percent of new HIV infections in 2021 occurred among key populations, which illustrates that the most marginalized are also the hardest hit,” Adeeba Kamarulzaman, President of the IAS – the International AIDS Society – and AIDS 2022 Interational Co-Chair, said.
Millions of lives at risk as progress against AIDS falters
MONTREAL/GENEVA, 27 July 2022 - Progress in prevention and treatment is faltering around the world, putting millions of people in grave danger. Eastern Europe and central Asia, Latin America, and the Middle East and North Africa have all seen increases in annual HIV infections over several years. In Asia and the Pacific, UNAIDS data now show new HIV infections are rising where they had been falling. Action to tackle the inequalities driving AIDS is urgently required to prevent millions of new HIV infections this decade and to end the AIDS pandemic.
New data from UNAIDS on the global HIV response reveals that during the last two years of COVID-19 and other global crises, progress against the HIV pandemic has faltered, resources have shrunk, and millions of lives are at risk as a result. The new report, In Danger, is being launched ahead of the International AIDS Conference in Montreal, Canada.
'The forgotten epidemic': World's largest HIV/AIDS conference will draw thousands to Montreal
July 27,2022 - Susan Schwartz - "Community engagement makes science better and results of uptake better. We learned this from HIV.”
Scientists advising the World Health Organization (WHO) on monkeypox say the window is closing to stop its spread, with cases currently doubling every two weeks, raising concerns that it will take several months for the outbreak to peak.
WHO Europe has forecast just over 27,000 monkeypox cases in 88 countries by Aug. 2, up from 17,800 cases in nearly 70 countries at the latest count.
Read more...
Window is closing to stop monkeypox spread, experts say
London - July 27,2022 - Jennifer Rigby - Scientists advising the World Health Organization (WHO) on monkeypox say the window is closing to stop its spread, with cases currently doubling every two weeks, raising concerns that it will take several months for the outbreak to peak.
WHO Europe has forecast just over 27,000 monkeypox cases in 88 countries by Aug. 2, up from 17,800 cases in nearly 70 countries at the latest count.
Read more...
Fauci says government must understand 'profound risk' of monkeypox to control spread
July 27,2022 - Dr. Anthony Fauci, chief medical adviser to President Biden, told NPR's All Things Considered Tuesday that, amid early transmission of monkeypox, it's important to understand "the extent of the spread, how it's spread, what population." He said it is a virus that medical professionals understand and one that they have available tools to use, unlike in the early months of the COVID-19 pandemic.
Read more...
AIDS 2022: The Silver Zone and the Disability Networking Zone
AIDS 2022 in Montreal
Join us at the Silver Zone (for older adults living with HIV)
and the Disability Networking Zone (DNZ) in the Global Village
at AIDS 2022 in Montreal, July 30 – August 1, 2022
Globally, the face of HIV is an ageing one. Although in supportive systems people are living longer with access to effective treatments, many older adults living with HIV and HIV Long-Term Survivors are coping with the lasting impact of untreated HIV, age-related comorbidities and loss. In the era of COVID-19 and “working to end the HIV epidemic”, many feel isolated and uncertain about the future.
The Silver Zone is a place for older people living with HIV to re-engage with the HIV community and follow the science on HIV and ageing; to feel included and celebrated.
_md.jpg)
AIDS 2022 / la Zone argent et la Zone de réseautage invalide
SIDA 2022 à Montréal
Rejoignez-nous à la Zone argent (pour les personnes âgées vivant avec le VIH) et à la zone de réseautage des personnes invalides (DNZ) dans le Village mondial à AIDS 2022 à Montréal,
du 30 juillet au 1er août 2022.
Dans le monde entier, le visage du VIH prend de l’âge. Et bien sûr, là où l’aide est disponible, les personnes vivent plus longtemps et ont accès à des traitements efficaces, mais nombreux sont les adultes âgés vivant avec le VIH et les survivants de longue date qui doivent faire face à l’impact à long terme d’un VIH non traité, ainsi qu’aux comorbidités et aux deuils liés à l’âge. À l’ère de la COVID-19 et malgré la volonté exprimée de mettre fin à l’épidémie de VIH, plusieurs se sentent isolés et inquiets face à l’avenir.
La Zone argent est un espace où les personnes âgées vivant avec le VIH peuvent se réengager auprès de la communauté touchée par le VIH et suivre la science concernant le virus et le vieillissement, pour se sentir incluses et respectées.
Today, watch live the launch of
In Danger: UNAIDS Global AIDS Update 2022
WEDNESDAY, 27 JULY, 14:30–15:30 EDT / 20:30 CET / 18:30 GMT
UNAIDS Global AIDS Update 2022 will be launched on Wednesday, 27th July in Montreal, Canada ahead of the opening of the International AIDS Conference.
The report is called ‘In Danger’ and contains powerful new data showing that the AIDS response is under threat. It shows how progress on HIV prevention has faltered, how global shocks have exacerbated risks ahead, and how resources for HIV are depleting.
The report demonstrates the cost of inaction and reveals the chilling human impact of the stalling of progress in the HIV response. It also sets out the courageous actions that are vital and urgent if the world is to prevent millions of new HIV infections and avoid an unending AIDS pandemic.
AIDS 2022 spotlights a game-changing tool to prevent sexually transmitted infections and key advances in HIV cure research
27 July 2022 (Montreal, Canada) - Studies highlighted at the 24th International AIDS Conference provide insights on new and existing strategies to help end the HIV epidemic.
New studies presented at AIDS 2022, the 24th International AIDS Conference, hosted by IAS – the International AIDS Society – demonstrate promising advances in the global HIV response.
Coronavirus Jumped to Humans at Least Twice at Market in Wuhan, China
July 26, 2022 - By Scott LaFee - Studies describe not only where the COVID-19 pandemic began, but the likelihood that the causative SARS-CoV-2 virus made the leap from animal hosts to people multiple times
In a pair of related studies, published July 26, 2022 online via First Release in Science, researchers at University of California San Diego, with colleagues on four continents, show that the origin of the COVID-19 pandemic in 2019 was at the Huanan Seafood Wholesale Market in Wuhan, China, and resulted from at least two instances of the SARS-CoV-2 virus jumping from live animal hosts to humans working or shopping there.
Activists call for more HIV funding from Ottawa as AIDS conference opens in Montreal
MONTREAL - July 26, 2022 - By Jacob Serebrin - As an international AIDS conference begins in Montreal this week, Canadian HIV and AIDS organizations say Canada’s response to the disease at home has stalled.
Advocates say federal funding for addressing HIV and AIDS has been frozen since 2008, even though the number of people in Canada living with the virus has risen by 25 per cent since then.
Read more...
ACTG announces publication of ACTIV-2 study in Cell Reports Medicine demonstrating rapid clearance of culturable SARS-CoV-2 following monoclonal antibody treatment
Los Angeles, Calif. - 26-JUL-2022 - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded to conduct research into COVID-19, today announced the publication of “Monoclonal Antibody Treatment Drives Rapid Culture Conversion in SARS-CoV-2 Infection,” in the journal Cell Reports Medicine. The publication reports on findings from the ACTIV-2/A5401 study of Outpatient Monoclonal Antibodies and Other Therapies and found that treatment with the monoclonal antibody bamlanivimab led to a rapid clearance in culturable virus from the nose that was far faster than the decline in viral RNA levels. While bamlanivimab is not currently in clinical use, the identical mechanisms of action of all clinically used SARS-CoV-2-targeting monoclonal antibodies make it likely that these findings will translate to other monoclonal antibodies.
World’s First HIV-Positive to HIV-Positive Heart Transplant Performed at Montefiore Health System
NEW YORK (July 26, 2022) - Transformative Surgery Occurs Almost a Decade After the Passage of the HIV Organ Policy Equity Act
The world’s first HIV-positive to HIV-positive heart transplant has been successfully performed at Montefiore Health System in the Bronx. The patient, in her sixties, suffered from advanced heart failure and received the life-saving donation, along with a simultaneous kidney transplant, in early Spring. After the four-hour surgery, she spent five weeks recovering in the hospital and now sees her transplant physicians at Montefiore for monitoring.
Activists say Canada’s response to HIV and AIDS has stalled, call for more funding
July 26, 2022 - Canadian HIV and AIDS organizations say an international AIDS conference opening in Montreal this week is shining a light on Canada’s lagging response to the disease.
Advocates say federal funding for HIV and AIDS has been frozen since 2008, even though the number of people in Canada living with HIV has risen by 25 per cent since then.
Read more...
ViiV HEALTHCARE TO PRESENT NEW DATA FROM INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT AIDS 2022
London, 25 July 2022 - Data to be presented include long-term and real-world data from portfolio of medicines, including long-acting and 2-drug regimens
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 29 abstracts from the company’s diverse portfolio of licensed treatment and prevention options at the 24th International AIDS Conference (AIDS 2022) being held in Montreal, Canada from 29 July – 2 August.
The real cause of HIV is inequality
July 24, 2022 - By Meg French - HIV leaders gather in Montreal this week for the 24th International AIDS Conference. Canada must recommit to ending AIDS as a public health threat.
When Phylis Wanjira learned she was HIV positive at a free testing clinic in her local Kenyan hospital, she refused to believe the news and collapsed in tears. Her father shunned her, making it clear there would be no place for an HIV-positive daughter at the family’s burial ground. Phylis tried to ignore her diagnosis, but when lesions started appearing on her face, she could no longer keep her secret.
Read more...
Advocates say Canada should commit $1.2 billion to fight against AIDS, TB and malaria
MONTREAL - July 24,2022 -Jacob Serebrin - Advocacy groups working to end extreme poverty say they hope Canada will use an upcoming international AIDS conference in Montreal to commit new funding for a global organization that fights AIDS, tuberculosis and malaria.
But the groups say they're worried Prime Minister Justin Trudeau's commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria will fall short.
Read more...
UNAIDS calls for urgent global response to Monkey Pox Public Health Emergency with rights-based public health and equitable access to vaccines
GENEVA, 23 July 2022 - UNAIDS today called on governments to respond urgently to the World Health Organization declaration of Monkey Pox as a Public Health Emergency of International Concern. WHO has received reports over 16 thousand cases in 75 countries. The outbreak is occurring particularly, but not exclusively, among gay men and other men who have sex with men.
BA.5 variant is 'one of the largest surges we’ve had'
GENEVA, 23 July 2022 - UW Medicine Infectious Diseases physician Dr. John Lynch says the BA.5 variant’s apparent strength in evading previous immune protection is driving a summer surge in new COVID-19 cases.
“We're probably at a number (of total cases) less than what we saw in January, but something very sizable and probably one of the largest surges we've had through the whole pandemic,” said Lynch, the medical director of infection control at Harborview Medical Center.
HIV criminalisation continues with over 270 arrests recorded in 39 countries in the last three years
22 July 2022 - Oguzhan Nuh - This is probably an underestimate – actual figure may be 700 cases
Since the first reported HIV-related prosecution in 1986, HIV criminalisation has occurred in at least 81 countries, according to a global report published today by the HIV Justice Network.
HIV criminalisation is “the unjust application of criminal laws, regulations and punitive policies against people living with HIV primarily based on their HIV-positive status.” Countries and jurisdictions can apply HIV-specific criminal laws (which exist in 82 countries) or general criminal laws (applied in 48 countries) against people living with HIV for non-disclosure to sexual partners, potential or perceived exposure to HIV, or alleged transmission.
Read more...
July 21: New International Awareness Day with an Aim to End HIV Stigma
21 July 2022 (LONDON, ENGLAND, UK, and WASHINGTON, DC, USA) - Commemorating the birthday of late South African AIDS activist Prudence Mabele (1971-2017), a consortium of community, medical, and urban health organizations today announced their joint effort to create #ZeroHIVStigmaDay (July 21), a new international awareness day calling attention to the persistent levels of stigma experienced by people living with and affected by HIV.
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
July 21, 2022 - FOSTER CITY, Calif.-- (BUSINESS WIRE )-- – Latest HIV Clinical Research and Development Data Drive the Next Wave of Innovation in Treatment, Prevention and Reaches Towards a Cure –
– Key Initiatives Highlight Role of Catalytic Collaboration to Help End the Epidemic for Everyone, Everywhere –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022). AIDS 2022 will be a hybrid conference, taking place in person in Montreal, Canada, as well as virtually, from July 29-August 2, 2022. As the leader in HIV innovation, the company will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs as part of its ongoing commitment to help end the HIV epidemic for everyone, everywhere.
Critics Worry Government Surveillance of HIV May Hurt More Than It Helps
July 20, 2022 - Sam Whitehead - One of the group’s main concerns involves consent. It says that many people living with HIV don’t know that genetic information about their strain of the virus could be used to link them to other people and that they would rather not have personal data used that way.
Novel HIV combination therapies could prevent viral escape and rebound
Jul 19, 2022 - A computer-based approach could help clinicians select the best combinations of broadly neutralising antibodies to treat HIV based on the virus’ genetics.
Carefully designed cocktails of broadly neutralising antibodies (bNAbs) could help treat HIV while minimising the risk of the virus escaping treatment, suggests a study published today in eLife.
Coming soon: news from AIDS 2022
19 July 2022 - Amelia Jones - The 24th International AIDS Conference (AIDS 2022) is taking place from 29 July to 2 August. It’s being held in Montréal, Canada, and virtually.
NAM aidsmap is delighted to be continuing its partnership with the International AIDS Society as an official scientific media partner for the conference.
Read more...
ECDC releases publications on COVID-19 vaccination strategies and joint ECDC-WHO report on considerations for respiratory diseases as guidance for the second half of the year
18 July 2022 - Following the joint statement from the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) on 11 July 2022, ECDC has released Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022. ECDC, in collaboration with the World Health Organization (WHO) Regional Office for Europe, has also published Operational considerations for respiratory virus surveillance in Europe.
Since 26 June 2022, the notification rates of COVID-19 cases in the European Union and European Economic Area (EU/EEA) remain high and have been increasing for the past 5 weeks. The rates among people aged 65 years and over increased in 23 of the 27 reporting countries. Though these increases are still relatively recent, they signal the start of a widespread wave driven by the BA.4 and BA.5 variants of concern (VOCs).
The Global Fund at the 24th International AIDS Conference in Montreal, Canada (29 July - 2 August 2022)
MONTREAL, Canada - July 14, 2022 - AIDS 2022 will call on the world to come together to re-engage and follow the science. It will define future research agendas, shift latest evidence to action, and chart a new consensus on overcoming the HIV epidemic as a threat to public health and individual well-being.
Celebrating 20 Years of AHF Uganda Cares!
KAMPALA, Uganda--(BUSINESS WIRE)-- (July 14, 2022 ) - Twenty years serving Uganda! AHF Uganda Cares, one of AIDS Healthcare Foundation's first and longest-running global programs, is celebrating its 20th anniversary this month under its “Keeping the Promise” pledge to save lives and combat HIV/AIDS in the country. AHF began providing lifesaving antiretroviral treatment (ART) to people living with HIV in Uganda in 2002.
Study finds treating precancerous growths in people with HIV reduces anal cancer by more than half
New Orleans, LA - July 14, 2022 - A team of researchers, including LSU Health New Orleans Infectious Diseases and Microbiology professor Michael Hagensee, MD, PhD, has shown for the first time that treating precancerous anal growths called high-grade squamous intraepithelial lesions (HSILs) in persons living with HIV significantly decreased the progression to anal cancer.
Monkeypox Virus Is Frequently Detected in Saliva, Semen and Other Clinical Samples From Infected Patients
14-Jul-2022 - by Barcelona Institute for Global Health - A new study, conducted on more than 140 samples from 12 infected patients, contributes to a better understanding of the dynamics of disease transmission
Viral DNA can be frequently detected in different clinical samples from monkeypox-infected patients, including saliva and semen, according to a new study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, and the Hospital Clínic of Barcelona. The study, published in Eurosurveillance, contributes to a better understanding of how this emerging disease is transmitted.
Nearly 800,000 doses of monkeypox vaccine may be in U.S. by end of July
July 13, 2022 - By Lena H. Sun and Laurie McGinley - Nearly 800,000 more doses of monkeypox vaccine could be ready for distribution in the United States by the end of July following a Food and Drug Administration inspection of a Danish vaccine plant and the expected authorization of the facility, part of an effort to control a record U.S. outbreak of the disease, according to the federal government.
Read more...
Six ways to improve HIV prevention pill uptake among young women in Zimbabwe
July 13, 2022 - Morten Skovdal - Adolescent girls and young women in sub-Saharan Africa have a very high risk of acquiring HIV. The latest global AIDS update report suggests that a staggering six out of seven new infections among 15-19-year-olds in sub-Saharan Africa are among girls.
Entrenched gender inequalities make young women and girls more vulnerable to coercive behaviour that leaves them unable to negotiate safe sex.
Best available therapy for AIDS-associated Kaposi sarcoma is cost effective in Africa
Jul 12, 2022 - BOSTON - A study that evaluated different chemotherapy regimens for advanced Kaposi sarcoma found that paclitaxel would save lives and be cost-effective in Kenya compared with more frequently used bleiomycin-vincristine
Although antiretroviral therapy has markedly improved survival in people with AIDS-associated Kaposi sarcoma (a type of cancer caused by a virus), the condition is still a life-threatening problem in low- and middle-income countries.
New research led by researchers at Massachusetts General Hospital (MGH) with Ugandan and Kenyan colleagues published in The Lancet Global Health indicates that the best available chemotherapy for Kaposi sarcoma, which is infrequently used in Africa, would improve clinical outcomes and be cost-effective at its current price compared with therapies that are most frequently provided in the region.
Quebec surpasses 10,000 vaccinations for monkeypox as cases rise to 284
July 12, 2022 - Joe Lofaro - Quebec has reached 10,000 vaccinations for monkeypox as the number of cases of the rare disease continues to rise.
The Ministry of Health said Tuesday the number of confirmed cases has gone up to 284, an increase of 36 cases from five days ago.
Read more...
Ottawa fast-tracking travel visas for AIDS conference amid sharp criticism
OTTAWA - July12, 2022 - By Mia Rabson -
The federal government is prioritizing temporary travel visas for people seeking to attend the International AIDS Conference in Montreal at the end of July.
But the conference begins in two weeks and hundreds of people hoping to attend are still in limbo about their travel plans. Many others, mostly from Africa, Asia and South America, already had their visa requests rejected, including some who received scholarships partially funded by the federal government in order to attend.
Read more...
CATIE welcomes Jody Jollimore
JULY 12, 2022 - CATIE’s board of directors is pleased to announce that Jody Jollimore will serve as our next executive director, starting September 6, 2022. Jody is no stranger to us or our partners, having served most recently as executive director of the Community-Based Research Centre (CBRC).
Preliminary information from some cases of monkeypox in several countries
JULY 12, 2022 - In this CATIE News bulletin we review findings from the United States, Portugal and Italy.
We now present preliminary findings from reports in several countries. Researchers have rushed to get information about the current outbreak into publication in order to help clinicians and researchers who may be treating people with monkeypox or conducting research on this condition. However, due to the sudden appearance of monkeypox in high-income countries and the rush to disseminate research findings, some of the initial reports have missing or incomplete data. This is typical in the first several months of any rapidly developing outbreak with a germ that was previously uncommon.
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 July 2022) – IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen
Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics
Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with human immunodeficiency virus (HIV) infection.
UCF Undergrads to Present at International HIV/AIDS Conference
July 11, 2022 – By Christin Senior - Three undergraduate students will present their health disparities research at the International AIDS Conference in Canada July 29-Aug. 2
Three undergraduate students at the Burnett School of Biomedical Sciences at the University of Central Florida have been selected to present their health disparities research at the International AIDS Conference in Montreal, Canada, July 29-Aug. 2. The conference is the largest and most prestigious HIV/AIDS research conference in the world and will feature infectious disease expert Anthony Fauci as the keynote speaker.
New $3.25M NIH grant to support research in oral manifestations of HIV, including mouth cancer
11-Jul-2022 – Researchers at the Case Western Reserve University School of Dental Medicine will use a $3.25 million grant from the National Institutes of Health (NIH) to better understand how HIV impacts the human body, from mouth lesions to oral cancer.
HIV is a virus that attacks the body’s immune system and interferes with its ability to fight infections. More than a third of HIV patients will develop some form of oral side effects, like mouth ulcers from immune systems and can greatly impact quality-of-life.
ECDC and EMA update recommendations on additional booster doses of COVID-19 vaccines
July 11, 2022 - The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) are recommending that second booster doses of COVID-19 vaccines be considered for people between 60 and 79 years old and people with medical conditions putting them at high risk of severe disease.
In April 2022, both agencies recommended that people over 80 years of age be considered for a second booster. However, the agencies noted at the time that it might be necessary to consider second boosters in people between 60 and 79 years old and vulnerable persons of any age if there was a resurgence of infections.
Move over, measles: Dominant Omicron subvariants BA.4 and BA.5 could be the most infectious viruses known to man
July 9, 2022 - BY ERIN PRATER - Globally dominant Omicron subvariants BA.4 and BA.5 are neck and neck with measles in the competition for the title of most infectious disease known to man, according to an Australian professor of biostatistics and epidemiology.
Read more...
World Hepatitis Day 2022
July 8, 2022 - July 28, 9 AM Pacific time
July 28th is World World Hepatitis Day, a day to raise awareness, educate and advocate. If you have events or resources you wish to share, please let us know. This page will be updated as more information comes in.
Immune system uses two-step verification to defend against HIV
Newswise — LA JOLLA, CA - July 8, 2022 - Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system. Scientists at Scripps Research and collaborators have now uncovered how our innate immune system – the body’s first line of quick defense in attacking foreign invaders – detects HIV-1, even when the virus is present in very small amounts.
UI Health team bikes 200 miles, raises $11K for HIV services
July 8, 2022 - A team of 19 staff members and providers from theUI Health Community Clinic Network at UIC biked 200 miles or more and raised more than $11,000 to support services for people living with and at risk for HIV during Ride for Life, June 18-19.
The Ride for Life annual fundraiser is the largest event of its kind in the Midwest, and the money raised helps the Test Positive Aware Network and community partners provide housing, health care and mental health services to thousands in Chicago.
One-time gene therapy injection could provide HIV treatment that may last a lifetime
Portland, Oregon - July 8, 2022 - By Franny White By Casey Williamson - OHSU researcher receives $5 million grant to study long-term suppression of human immunodeficiency virus in nonhuman primates
A new pre-clinical study in nonhuman primates will evaluate an experimental drug’s potential use as a gene therapy that could prevent people who have HIV from having to take daily antiviral drugs for the rest of their lives.
ECDC releases first update to its Rapid Risk Assessment on the monkeypox outbreak
July 8, 2022 - The European Centre of Disease Prevention and Control has today released the Rapid Risk Assessment Monkeypox multi-country outbreak - first update. Since early May 2022 and as of 7 July, cases of monkeypox have been reported in twenty-six European Union/European Economic Area (EU/EEA) countries. So far 4 908 cases have been reported in the EU/EEA, representing 65% of all cases reported worldwide in 2022 in this outbreak in non-endemic countries.
Human-to-human transmission of monkeypox occurs through the close contact of skin lesions of an infected person, through respiratory droplets in prolonged face-to-face contact, and through fomites.
Understanding the Structure of HIV Protein May Lead to Novel Treatments
July 7, 2022 - In a discovery that could spur the development of new therapies for more than 40 million HIV patients worldwide, scientists from Rutgers University and the Salk Institute determined the molecular structure of the HIV Pol polyprotein, a protein that plays a critical role in helping the virus propagate itself and spread throughout the body.
Their findings, published in Science Advances on July 6, may guide the creation of drugs that would bind to the protein and block its function.
Breaking the stigma of AIDS part of Raffanti’s long legacy
Jul. 7, 2022 - by Bill Snyder - On June 29 Stephen Raffanti, MD, MPH, hung up his scrubs at the Vanderbilt Comprehensive Care Clinic for the last time. It was a bittersweet moment for the man who helped lead Nashville out of the darkest days of the AIDS epidemic 30 years ago.
BC CENTRE FOR EXCELLENCE IN HIV/AIDS CELEBRATES 30 YEARS
July 7, 2022 - This year the BC Centre for Excellence in HIV/AIDS (BC-CfE) at St. Paul’s Hospital is celebrating its 30th anniversary. Since its inception in 1992, the advancements made by BC-CfE staff and its international collaborators have transformed HIV from a rapidly progressing fatal disease, to a chronic and manageable illness that is highly, and easily, preventable.
Read more...
A nasty disease is even nastier for patients with HIV. Now there's encouraging news
July 7, 2022 - MAX BARNHART - This new treatment offers a modest but significant increase in survival rates for those without HIV coinfection, from 88% to 96% compared to LAmB alone. For those coinfected with HIV, this combination treatment results in a substantial increase in efficacy, with survival rates moving from 55% to 88%.
Read more...
Imaging solves mystery of how large HIV protein functions to form infectious virus
LA JOLLA - 6 July 2022 - Detailed views of the HIV protein may lead to novel treatments against the virus
Understanding how HIV replicates within cells is key for developing new therapies that could help nearly 40 million people living with HIV globally. Now, a team of scientists from the Salk Institute and Rutgers University have for the first time determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, or the process through which the virus propagates itself and spreads through the body. Importantly, determining the molecule’s structure helps answer longstanding questions about how the protein breaks itself apart to advance the replication process. The discovery, published in Science Advances on July 6, 2022, reveals a new vulnerability in the virus that could be targeted with drugs.
IAS 2023: World’s largest scientific conference on HIV will be held in Brisbane and virtually
6 July 2022 - IAS – the International AIDS Society – has announced that IAS 2023, the 12th IAS Conference on HIV Science, will take place in Brisbane, Australia, and virtually from 23 to 26 July 2023. IAS 2023, being held at the Brisbane Convention and Exhibition Centre, will shine a spotlight on the world’s advances in HIV research.
UNAIDS applauds Argentina for the approval of its new human rights-based HIV law
4 July 2022 - UNAIDS congratulates the Argentinian Congress on the approval of a new law on a comprehensive response to HIV, viral hepatitis, tuberculosis and sexually transmitted infections (STIs). The bill, which has had input from a number of civil society organizations, replaces 30-year-old legislation and changes the country’s health approach from a biomedical approach to an approach more focused on gender and human rights. The new law calls for an end to stigma and discrimination against people living with HIV or STIs and aims to stop criminalization of HIV exposure or transmission.
Lessons learned from COVID-19 help Pakistan in the fight against HIV/AIDS
4 July 2022 - by Saadeqa Khan - The actions taken in response to COVID-19 are helping the 165,000 people nationwide living with HIV.
Since 2019, more than 50 children have died in the town due to HIV. A research report published in October 2019 revealed that 1,200 cases of HIV, including 900 children under 12, were linked to a paediatrician who reused unsterilised syringes and IV drips.
Scientists Discover Key to Hepatitis A Virus Replication, Show Drug Effectiveness
CHAPEL HILL, NC - July 4, 2022 - With no current treatments for hepatitis A, UNC School of Medicine scientists led by Stanley M. Lemon, MD, discovered how a protein and enzymes interact to allow hepatitis A virus to replicate, and they used a known drug to stop viral replication in an animal model.
The viral replication cycle is crucial for a virus to spread inside the body and cause disease. Focusing on that cycle in the hepatitis A virus (HAV), UNC School of Medicine scientists discovered that replication requires specific interactions between the human protein ZCCHC14 and a group of enzymes called TENT4 poly(A) polymerases. They also found that the oral compound RG7834 stopped replication at a key step, making it impossible for the virus to infect liver cells.
Hunter Reynolds, Artist Who Dressed Up AIDS, Dies at 62
July 3, 2022 - By Penelope Green - After he learned he was H.I.V. positive, he began making art — often performing as his gown-wearing alter ego — that told stories about the condition.
Mr. Reynolds died on June 12 at his home in Manhattan. He was 62. Wendy Olsoff, a founder of the P.P.O.W. gallery in TriBeCa, said the cause was an aggressive form of squamous cell carcinoma.
Read more...
People planning to attend HIV/AIDS conference in Montreal still struggling to get visas
July 2, 2022 - International AIDS organizations say people from Africa, South America and Asia who are planning to attend a major conference in Montreal are still struggling to get visas.
Last week, almost 250 organizations from around the world sent a joint letter to Immigration Minister Sean Fraser calling on him to take action to ensure participants can attend the International AIDS conference.
Read more...
New research studies health of HIV-positive moms' infants
July 1, 2022 - Heide Aungst - For 18 months, study leaders Claire Fraser, PhD, the Dean’s Endowed Professor of Medicine at UMSOM and director of IGS, and Man Charurat, PhD, MHS, professor of medicine at UMSOM and the division director of Epidemiology & Prevention at IHV, along with colleagues, followed a group of 272 Nigerian babies born to mothers with and without HIV. All mothers with HIV in this study were being treated with ART, and none transmitted the virus to their newborns.
Mathematical Model Helps Predict Anal Cancer Risk in Persons with HIV Infection
July 01, 2022 - Scott LaFee - Both cervical and anal cancer are caused by human papillomavirus. Both diseases also share a common precursor: abnormal cells known as high-grade squamous intraepithelial lesions (HSIL).
In cervical neoplasia, treatment of HSILs has been shown to reduce progression to cervical cancer. Recent published research suggests that the same holds true with anal cancer: HSIL treatment reduced the risk of progression to invasive anal cancer by 57 percent.
The Lancet Infectious Diseases: Monkeypox symptoms in patients attending London sexual health clinics differ from previous outbreaks, study of May 2022 UK outbreak suggests
1st July 2022 - The findings suggest that patients in this cohort had a higher prevalence of skin lesions in the genital and anal area and lower prevalence of tiredness and fever than in cases from previously studied outbreaks of monkeypox. Based on this study’s findings, the authors suggest current case definitions for ‘probable cases’ of monkeypox [1] should be reviewed to help identify cases.
|
